Health Care · Biological Products, (No Diagnostic Substances)

AVXL ANAVEX LIFE SCIENCES CORP. SEC Filings & Insider Trading Activity 2026

company
CIK 1314052111 filings
Russell 2000

AVXL at a glance

ANAVEX LIFE SCIENCES CORP. (AVXL, SEC CIK 1314052) filed its latest 10-K annual report on November 25, 2025, a 10-Q quarterly report on August 28, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding ANAVEX LIFE SCIENCES CORP. (AVXL) shares worth $44.2 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
27 funds
$44.2M · −1 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 5.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Jun 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged year over year; no products approved for commercial sale
  • Profitability not stated; clinical-stage company with no commercial revenue
  • Lead compound ANAVEX 2-73 prioritized for early Alzheimer’s disease, Rett syndrome, and Fragile X syndrome
  • Other assets ANAVEX 3-71, 1-41, and 1066 de-prioritized; development paused
  • Near-term focus on FDA engagement and data-driven regulatory strategy; additional funding or partnerships needed for paused assets

Risk Factors

  • Former CEO termination for Cause triggered potential litigation, inquiries, investigations, and enforcement actions
  • Arbitration demand filed June 2026 alleging wrongful termination
  • New York Supreme Court action filed July 2026 against four independent directors
  • FDA, SEC, and Nasdaq proceedings risk management distraction and reputational harm
  • Investor, patient, and partner confidence loss could pressure operations and stock price

AI summary of the AVXL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Terrie Kellmeyer, Ph.D., appointed President and CEO effective November 1, 2026, replacing interim leadership with a permanent appointment
  • Kellmeyer joins Anavex’s Board, strengthening alignment between operational execution and director oversight

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Terrie Kellmeyer appointed permanent CEO and President effective November 1, succeeding interim leadership
  • Extensive pharmaceutical experience across clinical development, regulatory affairs, and medical affairs supports drug-development execution
Filed Nov 2, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Three directors resigned effective October 28, 2026: Jiong Ma, Gautam Patel and Adrian Senderowicz
  • Board departures cited strategic disagreements with management and the remaining directors

Item 8.01: Other Events

  • Board reconstituted all three standing committees effective November 1, 2026
  • Claus van der Velden appointed Audit Committee chair
Filed Oct 20, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • DDI study completed with 65 participants at 30 mg; no serious adverse events in preliminary observations
  • ADME study completed with 8 participants at 30 mg; full safety and pharmacokinetic analyses remain pending

Item 8.01: Other Events

  • Blarcamesine clinical development update, covering completed ADME and drug-drug interaction studies
  • Study completion supports regulatory pharmacology package development for blarcamesine

AI summaries of AVXL 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for AVXL

Don't miss the next AVXL filing

  • Alerts as it files. A push when AVXL files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut AVXL, by share count.
  • Ask anything. An AI agent that reads every AVXL filing and answers with sources.

AVXL alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Paeger AxelANov 3, 2026-
Kellmeyer TerrieANov 3, 2026-
Velden Claus VanderANov 3, 2026-
Donhauser Peter D.O.ANov 3, 2026-
Boenisch SandraASep 24, 2026-
Boenisch SandraASep 24, 2026-
Boenisch SandraASep 24, 2026-
Boenisch SandraASep 24, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$55.8M-$52.9M-$51.4M
Net Income-$47.5M-$43.0M-$46.4M
Balance Sheet
Total Assets$154.4M$135.6M$103.8M
Equity$141.9M$120.3M$94.9M
ROE-33.5%-35.8%-48.9%
Per Share
EPS$-0.60$-0.52$-0.54
Cash Flow
Operating CF-$27.8M-$30.8M-$39.0M

Source: XBRL data in ANAVEX LIFE SCIENCES CORP. (AVXL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate AVXL share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
AVXL shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$44.2M
Q2 202628$59.5M
Q1 202628$77.5M
Q4 202524$82.6M
Q3 202524$188.0M
Q2 202524$191.2M
Q1 202523$114.1M
Q4 202421$118.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 199 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

AVXL filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 6, 2026--
4Nov 6, 2026--
4Nov 6, 2026--
4Nov 6, 2026--
8-KNov 3, 2026Analysis-
8-KNov 2, 2026Analysis-
8-KOct 20, 2026Analysis-
8-KOct 15, 2026Analysis-
4Sep 28, 2026--
8-KSep 28, 2026Analysis-
8-KSep 9, 2026Analysis-
8-KSep 2, 2026Analysis-
10-QAug 28, 2026Analysis
10-QAug 28, 2026Analysis
8-KAug 25, 2026Analysis-
8-KAug 17, 2026Analysis-
8-KAug 11, 2026Analysis-
8-KAug 3, 2026Analysis-
SC 13GJul 31, 2026-
8-KJul 30, 2026Analysis-
8-KJul 20, 2026--
8-KJun 26, 2026--
8-KMay 22, 2026-
8-KMay 15, 2026-
8-KMay 6, 2026-

Related Health Care companies

All Health Care →

AVXL SEC filings: frequently asked questions

Which institutions hold AVXL stock?

As of September 30, 2026, the largest ANAVEX LIFE SCIENCES CORP. (AVXL) holders among the 13F filers tracked by SignalX were BlackRock ($16.5 million), Vanguard Capital Management LLC ($8.3 million), Two Sigma Investments ($4.7 million), State Street Corp ($4.0 million), Vanguard Portfolio Management LLC ($1.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did AVXL report in its latest 8-K?

ANAVEX LIFE SCIENCES CORP. (AVXL) filed an 8-K on November 3, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Terrie Kellmeyer, Ph.D., appointed President and CEO effective November 1, 2026, replacing interim leadership with a permanent appointment.

What are the latest AVXL SEC filings?

ANAVEX LIFE SCIENCES CORP. (AVXL) filed its latest 10-K annual report on November 25, 2025, a 10-Q quarterly report on August 28, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 6, 2026.

What is AVXL's SEC CIK number?

ANAVEX LIFE SCIENCES CORP. (AVXL)'s SEC Central Index Key (CIK) is 1314052. EDGAR lists every AVXL filing under that number.

Ask anything about AVXL

The research agent reads AVXL's filings, financials, insider trades and 13F holders, then answers with sources.